David Flannery, a pediatric geneticist, is the new medical director of the American College of Medical Genetics and Genomics.
Flannery is a founding fellow at ACMG, co-chair of its Economics of Genetic Services Committee, as well as a member of its Professional Practice and Guidelines Committee and CPT and Reimbursement Subcommittee. He also represents ACMG on the American Medical Association's CPT Advisory Committee. Flannery is involved with a number of organizations that often work with ACMG, such as American Academy of Pediatrics and the US Food and Drug Administration.
Rodney Markin, chief technology officer at the University of Nebraska Medical Center, has joined Trovagene's board of directors. Markin is also a professor of pathology and microbiology at the University of Nebraska, a hepatic pathologist, and a leader in the field of lab automation. Trovagene, a San Diego-based firm that has developed a platform for monitoring cancer based on cell-free DNA in urine, also announced that previous board member Chris McGuigan has stepped down to pursue other opportunities.
Biogen Idec announced that William Young will retire as chairman of its board. Young has been a member of the company's board since 1997 and its chairman since 2010. With Young's departure, Stelios Papadopoulos will take over the chairmanship. Papadopoulos founded Exelixis in 1994 and heads up the drug company's board, and serves as vice chairman of Cowen & Co.